Ligand validation:4QAB

NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose

NAG is a Ligand Of Interest in 4QAB designated by the RCSB

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
4QAB_NAG_C_302	27%	43%	0.242	0.891	0.43	1.78	-	3	0	0	100%	0.9333
4QAB_NAG_A_302	16%	49%	0.295	0.867	0.62	1.36	-	2	0	0	100%	0.9333
4QAB_NAG_B_302	15%	37%	0.282	0.843	0.53	1.97	-	4	0	0	100%	0.9333
4QAB_NAG_D_302	6%	58%	0.264	0.7	0.48	1.12	-	1	0	0	100%	0.9333
4QAB_NAG_H_302	5%	76%	0.311	0.706	0.3	0.62	-	-	0	0	100%	0.9333
4QAB_NAG_J_302	4%	77%	0.381	0.759	0.29	0.61	-	-	0	0	100%	0.9333
4QAB_NAG_E_302	3%	54%	0.374	0.729	0.52	1.26	-	1	0	0	100%	0.9333
4QAB_NAG_I_302	1%	70%	0.449	0.639	0.36	0.75	-	1	1	0	100%	0.9333
4QAB_NAG_G_302	1%	70%	0.505	0.628	0.37	0.75	-	1	0	0	100%	0.9333
7DJI_NAG_A_402	76%	57%	0.116	0.954	0.55	1.08	-	2	0	0	100%	0.9333
5J5I_NAG_J_301	74%	76%	0.135	0.966	0.26	0.66	-	-	0	0	100%	0.9333
5J5G_NAG_E_302	57%	70%	0.148	0.924	0.44	0.68	-	-	0	0	100%	0.9333
3U8J_NAG_G_213	36%	47%	0.18	0.875	0.52	1.53	-	3	1	0	100%	0.9333
4QAC_NAG_A_303	29%	23%	0.175	0.834	1.72	1.61	4	3	0	0	100%	0.9333
1OC7_NAG_A_500	100%	60%	0.04	0.991	0.61	0.9	-	1	0	0	100%	0.9333
1OC6_NAG_A_500	100%	67%	0.041	0.988	0.46	0.8	-	1	0	0	100%	0.9333
1UWC_NAG_A_262	100%	54%	0.046	0.99	0.81	0.95	-	-	0	0	100%	0.9333
6ZE6_NAG_B_703	99%	52%	0.044	0.984	0.78	1.07	-	2	0	0	100%	0.8667
6ZE2_NAG_B_704	99%	56%	0.042	0.979	0.73	0.95	-	1	0	0	100%	0.9333

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM133198.